【AHEALTH 7090 交流专区】艾柏士保健

icy97

SUMMARY OF KEY FINANCIAL INFORMATION 31/12/2014

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		31/12/2014	31/12/2013	31/12/2014	31/12/2013
		$$'000	$$'000	$$'000	$$'000

1	Revenue	123,305	106,210	499,237	418,451
2	Profit/(loss) before tax	12,671	10,566	45,624	40,615
3	Profit/(loss) for the period	9,545	7,643	33,977	30,122
4	Profit/(loss) attributable to ordinary equity holders of the parent	9,545	7,643	33,977	30,123
5	Basic earnings/(loss) per share (Subunit)	8.13	6.50	28.91	25.63
6	Proposed/Declared dividend per share (Subunit)	6.00	6.00	9.50	10.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	2.2200		2.5100

icy97

SUMMARY OF KEY FINANCIAL INFORMATION 31 Mar 2015

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		31 Mar 2015	31 Mar 2014	31 Mar 2015	31 Mar 2014
		$$'000	$$'000	$$'000	$$'000

1	Revenue	140,064	130,927	140,064	130,927
2	Profit/(loss) before tax	11,880	12,622	11,880	12,622
3	Profit/(loss) for the period	8,446	9,468	8,446	9,468
4	Profit/(loss) attributable to ordinary equity holders of the parent	8,446	9,438	8,446	9,438
5	Basic earnings/(loss) per share (Subunit)	7.21	8.06	7.21	8.06
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.00	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	2.2900		2.2200

icy97

SUMMARY OF KEY FINANCIAL INFORMATION 30 Jun 2015

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		30 Jun 2015	30 Jun 2014	30 Jun 2015	30 Jun 2014
		$$'000	$$'000	$$'000	$$'000

1	Revenue	124,279	122,493	264,343	253,420
2	Profit/(loss) before tax	9,076	10,050	20,956	22,672
3	Profit/(loss) for the period	6,602	7,554	15,048	17,022
4	Profit/(loss) attributable to ordinary equity holders of the parent	6,603	7,522	15,049	16,960
5	Basic earnings/(loss) per share (Subunit)	5.64	6.42	12.85	14.48
6	Proposed/Declared dividend per share (Subunit)	5.00	3.50	5.00	3.50
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	2.2900		2.2200

icy97

EX-date	14 Sep 2015
Entitlement date	17 Sep 2015
Entitlement time	05:00 PM
Entitlement subject	Interim Dividend
Entitlement description	Interim Single-Tier Dividend of 5.00 sen per share in respect of the financial year ending 31 December 2015.
Period of interest payment	to
Financial Year End	31 Dec 2015
Share transfer book & register of members will be	to   closed from (both dates inclusive) for the purpose of determining the entitlement
Registrar or Service Provider name, address, telephone no	BOARDROOM CORPORATE SERVICES (KL) SDN BHDLot 6.05, Level 6, KPMG Tower8, First AvenueBandar Utama47800 Petaling JayaSelangor Darul EhsanTel: 03-77201188Fax: 03-77201111
Payment date	30 Sep 2015
a.Securities transferred into the Depositor's Securities Account before 4:00 pm in respect of transfers	17 Sep 2015
b.Securities deposited into the Depositor's Securities Account before 12:30 pm in respect of securities exempted from mandatory deposit
c. Securities bought on the Exchange on a cum entitlement basis according to the Rules of the Exchange.
Number of new shares/securities issued (units) (If applicable)
Entitlement indicator	Currency
Currency	Malaysian Ringgit (MYR)
Entitlement in Currency	0.0500
Par Value	Malaysian Ringgit (MYR) 1.000

icy97

SUMMARY OF KEY FINANCIAL INFORMATION 30 Sep 2015

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		30 Sep 2015	30 Sep 2014	30 Sep 2015	30 Sep 2014
		$$'000	$$'000	$$'000	$$'000

1	Revenue	128,268	122,512	392,611	375,932
2	Profit/(loss) before tax	7,721	10,281	28,677	32,953
3	Profit/(loss) for the period	5,388	7,410	20,436	24,432
4	Profit/(loss) attributable to ordinary equity holders of the parent	5,381	7,382	20,430	24,342
5	Basic earnings/(loss) per share (Subunit)	4.59	6.30	17.44	20.78
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.00	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	2.3400		2.2200

icy97

SUMMARY OF KEY FINANCIAL INFORMATION 31 Dec 2015

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		31 Dec 2015	31 Dec 2014	31 Dec 2015	31 Dec 2014
		$$'000	$$'000	$$'000	$$'000

1	Revenue	134,248	123,305	526,859	499,237
2	Profit/(loss) before tax	16,912	12,671	45,589	45,624
3	Profit/(loss) for the period	13,827	9,545	34,263	33,977
4	Profit/(loss) attributable to ordinary equity holders of the parent	13,806	9,522	34,236	33,864
5	Basic earnings/(loss) per share (Subunit)	11.79	8.13	29.23	28.91
6	Proposed/Declared dividend per share (Subunit)	6.00	6.00	11.00	9.50
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	2.4600		2.2200

Remarks :

The Board of Directors has recommended a final single-tier dividend of 6 sen per ordinary share of RM1.00 each in respect of financial year ended 31 December 2015 subject to approval of the shareholders at the forthcoming Seventeenth Annual General Meeting of the Company.

icy97

EX-date	01 Jun 2016
Entitlement date	03 Jun 2016
Entitlement time	05:00 PM
Entitlement subject	Final Dividend
Entitlement description	Final single-tier dividend of 6.00 sen per ordinary share of RM1.00 each for the financial year ended 31 December 2015.
Period of interest payment	to
Financial Year End	31 Dec 2015
Share transfer book & register of members will be	to   closed from (both dates inclusive) for the purpose of determining the entitlement
Registrar or Service Provider name, address, telephone no	BOARDROOM CORPORATE SERVICES (KL) SDN BHDLot 6.05, Level 6, KPMG Tower8, First AvenueBandar Utama47800 Petaling JayaTel: 03-7720 1188Fax: 03-7720 1111
Payment date	17 Jun 2016
a.Securities transferred into the Depositor's Securities Account before 4:00 pm in respect of transfers	03 Jun 2016
b.Securities deposited into the Depositor's Securities Account before 12:30 pm in respect of securities exempted from mandatory deposit
c. Securities bought on the Exchange on a cum entitlement basis according to the Rules of the Exchange.
Number of new shares/securities issued (units) (If applicable)
Entitlement indicator	Currency
Currency	Malaysian Ringgit (MYR)
Entitlement in Currency	0.0600
Par Value	Malaysian Ringgit (MYR) 1.000

icy97

营业额增 Apex Healthcare首季净利扬16.2%
By Billy Toh / theedgemarkets.com   | May 18, 2016 : 6:57 PM MYT

（吉隆坡18日讯）营业额走高，带动Apex Healthcare Bhd首季净利按年上扬16.19%。

截至3月杪首季净利达981万令吉，或每股8.38仙，相比上财年同期的845万令吉，或每股7.21仙。

该公司指出，联号公司 Straits Apex私人有限公司的100万令吉贡献，其中40万令吉是令吉汇率走强的未实现外汇收益，也推高净利。

首季营业额增5.29%至1亿4748万令吉，同期为1亿4006万令吉。

Apex指出，所有业务子公司的收入符合预期，新加坡子公司和本地消费保健产品和医药批发业务贡献良好。

该公司补充，核心业务的前景依然受看好。

“非专利药需求提高，以降低医疗成本、日益富裕，以及某些国家人口老化，提振市场需求。”

可是，全球经济不明朗、油价保持低位，以及外汇波动，导致经商环境充满挑战。

“我们已降低2016年的预期。如无意外，董事部预计本财年将交出满意表现。”

（编译：陈慧珊）

SUMMARY OF KEY FINANCIAL INFORMATION 31 Mar 2016

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		31 Mar 2016	31 Mar 2015	31 Mar 2016	31 Mar 2015
		$$'000	$$'000	$$'000	$$'000

1	Revenue	147,478	140,064	147,478	140,064
2	Profit/(loss) before tax	12,366	11,880	12,366	11,880
3	Profit/(loss) for the period	9,819	8,446	9,819	8,446
4	Profit/(loss) attributable to ordinary equity holders of the parent	9,813	8,446	9,813	8,446
5	Basic earnings/(loss) per share (Subunit)	8.38	7.21	8.38	7.21
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.00	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)

icy97

Date of change	18 May 2016
Name	MR KEE KIRK CHUEN
Age	51
Gender	Male
Nationality	Singapore
Designation	Director
Directorate	Non Independent and Non Executive
Type of change	Appointment
Qualifications	MBAM.Eng (Master of Engineering)
Working experience and occupation	1989 - 2004, Executive Director, Apex Pharmacy International Pte Ltd2005 - 2007, Deputy Director, National Council of Social Service2007 - 2009, Director, Apex Holdings Pte Ltd2010 - Present, Deputy General Manager, Temasek Cares CLG Ltd
Directorships in public companies and listed issuers (if any)	None
Family relationship with any director and/or major shareholder of the listed issuer	Brother of Dr Kee Kirk Chin, Chairman and Chief Executive Officer
Any conflict of interests that he/she has with the listed issuer	None
Details of any interest in the securities of the listed issuer or its subsidiaries	1) Direct interest - 46,875 ordinary shares of RM1.00 each2) Indirect interest - 48,335,956 ordinary shares of RM1.00 each
Due Date for MAP	18 Sep 2016

icy97

Apex Healthcare次季净利飙升46% 营业额走高 派息5.5仙
By Billy Toh / theedgemarkets.com   | August 17, 2016 : 8:37 PM MYT

（吉隆坡17日讯）Apex Healthcare Bhd 2016财政年次季净利飙涨46%至965万令吉，同期净赚660万令吉，归因于营业额增长18%。

该集团今日向大马交易所发文告报备，2016财年次季（截至2016年6月30日）营业额报1亿4670万令吉，同期录得1亿2430万令吉，营收走低主要是政府实施消费税（GST）所致。

同时，Apex Healthcare也共享旗下一家联号公司的86万令吉盈利，相比上财年同期蒙亏54万令吉。

“所有子公司的营业额在预期之内，外加来自集团品牌的医药与消费产品、分销机构、马新两国的医药批发业务的贡献强稳。”

然而，由于进口原料和制成品成本企高，该集团次季盈利赚幅仍持续承压。

与此同时，Apex Healthcare也宣布，2016财年派发每股5.5仙的单层中期股息，派息日定于9月30日。

总结上半年的业绩表现，该集团净赚1946万令吉，同期则录得1505万令吉，涨幅为29%；营业额也从上财年同期的2亿6434万令吉，年增11%至2亿9416万令吉。

“全球经济不稳定和外汇波动，致使营运环境充满挑战，我们依然维持2016年的温和预测。如无任何意外，我们预见，集团2016财年将取得令人满意的表现。”

（编译：倪嫣鴽）

SUMMARY OF KEY FINANCIAL INFORMATION 30 Jun 2016

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		30 Jun 2016	30 Jun 2015	30 Jun 2016	30 Jun 2015
		$$'000	$$'000	$$'000	$$'000

1	Revenue	146,685	124,279	294,163	264,343
2	Profit/(loss) before tax	12,313	9,076	24,679	20,956
3	Profit/(loss) for the period	9,655	6,602	19,474	15,048
4	Profit/(loss) attributable to ordinary equity holders of the parent	9,649	6,603	19,462	15,049
5	Basic earnings/(loss) per share (Subunit)	8.24	5.64	16.61	12.85
6	Proposed/Declared dividend per share (Subunit)	5.50	5.00	5.50	5.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	2.5500		2.4600

icy97

EX-date	13 Sep 2016
Entitlement date	15 Sep 2016
Entitlement time
Entitlement subject	Interim Dividend
Entitlement description	Interim single-tier dividend of 5.5 sen per ordinary share of RM1.00 each for the financial year ending 31 December 2016.
Period of interest payment	to
Financial Year End	31 Dec 2016
Share transfer book & register of members will be	to   closed from (both dates inclusive) for the purpose of determining the entitlement
Registrar or Service Provider name, address, telephone no	BOARDROOM CORPORATE SERVICES (KL) SDN BHDLot 6.05, Level 6, KPMG Tower8, First AvenueBandar Utama47800 Petaling JayaTel: 03-77201188Fax: 03-77201111
Payment date	30 Sep 2016
a.Securities transferred into the Depositor's Securities Account before 4:00 pm in respect of transfers	15 Sep 2016
b.Securities deposited into the Depositor's Securities Account before 12:30 pm in respect of securities exempted from mandatory deposit
c. Securities bought on the Exchange on a cum entitlement basis according to the Rules of the Exchange.
Number of new shares/securities issued (units) (If applicable)
Entitlement indicator	Currency
Currency	Malaysian Ringgit (MYR)
Entitlement in Currency	0.055
Par Value	Malaysian Ringgit (MYR) 1.000

icy97

耗资6800万
APEX保健建新制药厂

2016年9月16日
（吉隆坡15日讯）APEX保健（AHEALTH，7090，主板消费产品股）宣布，独资子公司Xepa-Soul Pattinson（马）私人有限公司（简称Xepa），将在马六甲Cheng工业园，兴建新的药丸制药厂，成本总值6800万令吉。

该公司向马交所报备，新制药厂毗邻Xepa现有的制药厂，新厂设备包括生产机械和多层停车场。

产能见顶

根据该公司文告，新的厂房放眼制药应付海内外市场需求，且为了降低人为错误，也增加了自动化和数码控制系统，同时扩大了建筑物管理系统。

新厂建峻后，将提升公司的药丸产能，有助于未来的发展策略。

APEX保健指出，Xepa现有的药丸制造厂，于1996年开始启用至今，已达最大产量，且已无法再翻新来加大产能和产量。

目前，新制药厂已完成设计工作，即将针对建筑和器材招标。

该公司预计，将于今年末季动工，如无意外，2018年下半年可开始生产。

同时，APEX保健将以内部资金和外部贷款完成该计划。【e南洋】

Type	Announcement
Subject	OTHERS
Description	Apex Healthcare Berhad - Construction of a new Oral Solid Dosage manufacturing facility (SPP NOVO) at Cheng Industrial Estate Melaka by Xepa-Soul Pattinson (Malaysia) Sdn Bhd, a wholly-owned subsidiary of Apex Healthcare Berhad.
The Board of Directors of Apex Healthcare Berhad (“AHB” or “the Company”) is pleased to announce that its wholly owned subsidiary, Xepa-Soul Pattinson (Malaysia) Sdn Bhd (“Xepa”), will be constructing a new oral solid dosage manufacturing facility (“SPP NOVO”) on its land situated at Lot 1-5, Jalan TTC 1, Cheng Industrial Estate, 75250 Melaka, Malaysia. SPP NOVO will be a newly constructed stand-alone facility adjacent to Xepa’s current manufacturing facilities on the same campus at Cheng Industrial Estate. The estimated cost of SPP NOVO is RM 68.0 million, including production machineries and an integrated multi-storey carpark. For full details of the announcement, please refer to the attached file. This announcement is dated 15 September 2016.

http://www.bursamalaysia.com/market/listed-companies/company-announcements/5207285

Attachments AHB Announcement_construction of SPP NOVO.pdf

icy97

SUMMARY OF KEY FINANCIAL INFORMATION 30 Sep 2016

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		30 Sep 2016	30 Sep 2015	30 Sep 2016	30 Sep 2015
		$$'000	$$'000	$$'000	$$'000

1	Revenue	142,960	128,268	437,123	392,611
2	Profit/(loss) before tax	11,536	7,721	36,215	28,677
3	Profit/(loss) for the period	8,748	5,388	28,222	20,436
4	Profit/(loss) attributable to ordinary equity holders of the parent	8,736	5,381	28,198	20,430
5	Basic earnings/(loss) per share (Subunit)	7.46	4.59	24.07	17.44
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.00	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	2.5700		2.4600

icy97

APEX颁1870万建厂合约

2016年12月23日
（吉隆坡22日讯）APEX保健（AHEALTH，7090，主板消费产品股）委任Erallex私人有限公司为新药丸制药厂的主要承包商，合约价值1870万令吉。

该公司今日向马交所报备，通过独资子公司Xepa-Soul Pattinson颁发合约，兴建工程将在2个星期后开始，并在13个月内竣工。

APEX保健指出，该合约不会对该公司2016财年的盈利和净资产有显著的影响，也不会影响该公司的资本和股权结构。

9月15日，APEX保健向马交所报备，将在马六甲Cheng工业园兴建新的药丸制药厂。【e南洋】

Type	Announcement
Subject	OTHERS
Description	Apex Healthcare Berhad - Construction of a new Oral Solid Dosage manufacturing facility ("SPP NOVO") at Cheng Industrial Estate Melaka by Xepa-Soul Pattinson (Malaysia) Sdn Bhd, a wholly-owned subsidiary of Apex Healthcare Berhad
The Board of Directors of Apex Healthcare Berhad is pleased to announce that its wholly owned subsidiary, Xepa-Soul Pattinson (Malaysia) Sdn Bhd, had on 22 December 2016 awarded the tender for the Main Contractor for SPP Novo to Erallex Sdn. Bhd. for a contract sum of RM18.70 million. For full details of the announcement, please refer to the attached file. This announcement is dated 22 December 2016.

http://www.bursamalaysia.com/market/listed-companies/company-announcements/5297053

Attachments AHB Announcement- Construction of SPP Novo (22 December 2016).pdf

icy97

SUMMARY OF KEY FINANCIAL INFORMATION 31 Dec 2016

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		31 Dec 2016	31 Dec 2015	31 Dec 2016	31 Dec 2015
		$$'000	$$'000	$$'000	$$'000

1	Revenue	144,146	134,248	581,269	526,859
2	Profit/(loss) before tax	10,079	17,165	46,294	45,842
3	Profit/(loss) for the period	6,766	13,827	34,988	34,263
4	Profit/(loss) attributable to ordinary equity holders of the parent	6,756	13,806	34,954	34,236
5	Basic earnings/(loss) per share (Subunit)	5.77	11.79	29.84	29.23
6	Proposed/Declared dividend per share (Subunit)	6.00	6.00	11.50	11.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	2.6600		2.4600

icy97

EX-date	31 May 2017
Entitlement date	02 Jun 2017
Entitlement time
Entitlement subject	Final Dividend
Entitlement description	Final single-tier dividend of 6.00 sen per ordinary share for the financial year ended 31 December 2016
Period of interest payment	to
Financial Year End	31 Dec 2016
Share transfer book & register of members will be	to   closed from (both dates inclusive) for the purpose of determining the entitlement
Registrar or Service Provider name, address, telephone no	BOARDROOM CORPORATE SERVICES (KL) SDN BHDLot 6.05, Level 6, KPMG Tower8, First AvenueBandar Utama47800 Petaling JayaSelangor Darul EhsanTel:0377201188Fax:0377201111
Payment date	16 Jun 2017
a.Securities transferred into the Depositor's Securities Account before 4:00 pm in respect of transfers	02 Jun 2017
b.Securities deposited into the Depositor's Securities Account before 12:30 pm in respect of securities exempted from mandatory deposit
c. Securities bought on the Exchange on a cum entitlement basis according to the Rules of the Exchange.
Number of new shares/securities issued (units) (If applicable)
Entitlement indicator	Currency
Currency	Malaysian Ringgit (MYR)
Entitlement in Currency	0.06
Par Value	Malaysian Ringgit (MYR) 0.000

icy97

Apex Healthcare首季净利年增3%
Syahirah Syed Jaafar/theedgemarkets.com
May 17, 2017 19:57 pm MYT

（吉隆坡17日讯）Apex Healthcare Bhd 2017财政年首季（截至2017年3月31日止）净利年增近3%至1010万令吉，或每股8.61仙，相较于上财年同季的981万令吉，或每股8.38仙。

营业额也从上财年同季的1亿4748万令吉，按年增长4.9%至1亿5465万令吉。

Apex Healthcare今日向大马交易所报备，所有业务的营业额表现皆符合预期，而该集团在大马和新加坡政府部门录得的销售也取得良好进展。

Apex Healthcare补充道，集团旗下品牌的3项新药品在2017财年首季也顺利推出市面。

“我们认为，制药、营销和分销药品和消费者医疗保健产品的前景依然保持正面。”

该集团指出，由于制药厂继续专注于仿制药生产，以降低医疗保健成本，外加富裕和经多见广的消费者着重医疗保健产品的质量与价值，以及某些国家人口老龄化，这些因素也带动市场需求。

若无任何意外，Apex Healthcare估计，集团2017年将再次取得令人满意的业绩表现。

（编译：倪嫣鴽）

SUMMARY OF KEY FINANCIAL INFORMATION 31 Mar 2017

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		31 Mar 2017	31 Mar 2016	31 Mar 2017	31 Mar 2016
		$$'000	$$'000	$$'000	$$'000

1	Revenue	154,652	147,478	154,652	147,478
2	Profit/(loss) before tax	12,912	12,366	12,912	12,366
3	Profit/(loss) for the period	10,099	9,819	10,099	9,819
4	Profit/(loss) attributable to ordinary equity holders of the parent	10,091	9,813	10,091	9,813
5	Basic earnings/(loss) per share (Subunit)	8.61	8.38	8.61	8.38
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.00	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	2.7500		2.6600

icy97

郭孔丰晋APEX保健大股东

2017年7月22日
（吉隆坡21日讯）世界糖王郭鹤年侄子郭孔丰，晋升为APEX保健（AHEALTH，7090，主板消费产品股）的大股东，间接持有40.61%股权。

间接持股40.61%

APEX保健向交易所报备，郭孔丰上周四（13日），收购了仁恒鹏瑞利投资（新加坡）私人有限公司的4757万股股权。

同日，仁恒鹏瑞利投资收购了联合工程有限公司（UEL）的33.5%股权。

UEL通过子公司UE UMC私人有限公司，持有Apex药剂控股私人有限公司的30%股权。

而Apex药剂控股，持有APEX保健的40.61%股权，让郭孔丰得以间接持有。

仁恒鹏瑞利投资是由仁恒置地、鹏瑞利置地集团、郭孔丰及丰益国际所成立的联营公司。

其中，郭孔丰也是丰益国际的联合创办人、主席兼总执行长。【e南洋】

Notice of Interest Sub. S-hldr (Section 137 of CA 2016)

APEX HEALTHCARE BERHAD

Particulars of Substantial Securities Holder

Name	YANLORD PERENNIAL INVESTMENT (SINGAPORE) PTE. LTD.
Address	8 Shenton Way #45-01 AXA Tower 068811 Singapore.
Company No.	201715887D
Nationality/Country of incorporation	Singapore
Descriptions (Class)	Ordinary Shares
Name & address of registered holder	Apex Pharmacy Holdings Sdn Bhd1-5 Jalan TTC 1Cheng Industrial Estate75250 MelakaMalaysia

Date interest acquired & no of securities acquired
Date interest acquired	13 Jul 2017
No of securities	47,571,956
Circumstances by reason of which Securities Holder has interest	Yanlord Perennial Investment (Singapore) Pte. Ltd. ("Yanlord") has acquired 33.5% of the total voting shares in United Engineers Limited ("UEL") pursuant to a sale and purchase agreement dated 13 July 2017.As a result of the acquisition, Yanlord has deemed interest in Apex Healthcare Berhad through the interest held by UE UMC Pte Ltd, a wholly-owned subsidiary of UEL by virtue of Section 8 of the Companies Act 2016.
Nature of interest	Indirect Interest
Total no of securities after change
Direct (units)
Direct (%)
Indirect/deemed interest (units)	47,571,956
Indirect/deemed interest (%)	40.609
Date of notice	17 Jul 2017
Date notice received by Listed Issuer	20 Jul 2017

icy97

Type	Announcement
Subject	OTHERS
Description	Apex Healthcare Berhad ("AHB" or "the Company")- Clarification on News Article appearing on THE STAR ONLINE titled "Wilmar's billionaire CEO emerges as Apex Healthcare's substantial shareholder" on 21 July 2017
We refer to the aforesaid article, in particular the following paragraphs:- (a) “United Engineers Ltd (“UEL”), one of Singapore’s oldest firms (founded in 1912), has an existing 40.61% stake in Malacca-based pharmaceutical product maker Apex Healthcare Bhd.” (b) “UEL-owned Apex Healthcare posted group earnings of RM34.95mil on revenue of RM581.27mil for the financial year ended Dec 31, 2016.” The Board of Directors of AHB wishes to clarify that UEL does not own a direct 40.61% stake in AHB. UEL is only deemed to have an interest in AHB through its wholly-owned subsidiary, namely UE UMC Pte Ltd which in turn owns 30% equity interest in Apex Pharmacy Holdings Sdn Bhd, which has a direct interest of 40.61% in Apex Healthcare Berhad. Therefore, it is incorrect to describe AHB as “UEL-owned”. This announcement is dated 21 July 2017.

icy97

APEX保健次季赚1030万

2017年8月17日
（吉隆坡16日讯）APEX保健（AHEALTH，7090，主板消费产品股）截至6月杪次季，净利按年增加6.72%至1029万7000令吉，或每股8.79仙；并宣布派息每股5.5仙。

APEX保健向交易所报备，公司上财年同期净赚964万9000令吉。

次季营业额也涨5.87%，从上财年同期的1亿4668万5000令吉，增加至1亿5529万7000令吉。

累计首半年，净利按年增4.76%至2038万8000令吉；营业额则增加5.37%至3亿994万9000令吉。

另外，APEX保健也派息每股5.5仙，除权日及享有权益日，落在下个月13日及15日。【e南洋】

SUMMARY OF KEY FINANCIAL INFORMATION 30 Jun 2017

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		30 Jun 2017	30 Jun 2016	30 Jun 2017	30 Jun 2016
		$$'000	$$'000	$$'000	$$'000

1	Revenue	155,297	146,685	309,949	294,163
2	Profit/(loss) before tax	13,453	12,313	26,365	24,679
3	Profit/(loss) for the period	10,300	9,655	20,399	19,474
4	Profit/(loss) attributable to ordinary equity holders of the parent	10,297	9,649	20,388	19,462
5	Basic earnings/(loss) per share (Subunit)	8.79	8.24	17.40	16.61
6	Proposed/Declared dividend per share (Subunit)	5.50	5.50	5.50	5.50
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	2.7800		2.6600